Healthcare - Biotechnology - NASDAQ - DK
$ 126.51
1.79 %
$ 7.26 B
Market Cap
-13.89
P/E
BALANCE SHEET
826 M
ASSETS
971 M
LIABILITIES
-146 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Ascendis Pharma A/S
| Current Assets | 703 M |
| Cash & Short-Term Investments | 399 M |
| Receivables | 55.8 M |
| Other Current Assets | 248 M |
| Non-Current Assets | 123 M |
| Long-Term Investments | 5.69 M |
| PP&E | 111 M |
| Other Non-Current Assets | 6.55 M |
| Current Liabilities | 197 M |
| Accounts Payable | 94.6 M |
| Short-Term Debt | 25.4 M |
| Other Current Liabilities | 77.4 M |
| Non-Current Liabilities | 774 M |
| Long-Term Debt | 619 M |
| Other Non-Current Liabilities | 155 M |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||
| Cash & Cash Equivalents | 392.2 | 444.8 | 446.3 | 584.5 | 598.1 | 277.9 | 195.4 | 180.3 | 119.6 | 50.2 | 19.4 | 14.5 | 15.7 |
| Short Term Investments | 7.3 | 290.7 | 235.8 | 134.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 55.8 | 11.9 | 2.2 | 0.4 | 0.8 | 2.6 | 2.4 | 0.3 | 1.1 | 1.3 | 1.7 | 6.1 | 2.0 |
| Inventory | 208.9 | 130.7 | 75.4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Other Current Assets | 38.6 | 45.4 | 46.2 | 14.0 | 7.6 | 12.4 | 6.9 | 2.0 | 3.8 | 0.6 | 64 K | 90 K | 0.3 |
| Total Current Assets | 702.7 | 923.5 | 805.9 | 740.1 | 611.2 | 292.9 | 204.6 | 184.0 | 125.7 | 53.2 | 21.2 | 20.7 | 18.0 |
| PP&E | 110.6 | 129.1 | 126.0 | 108.1 | 45.1 | 4.3 | 2.6 | 2.4 | 2.4 | 1.9 | 2.0 | 1.2 | 1.3 |
| Intangible Assets | 0.9 | 1.3 | 1.8 | 2.2 | 0 | 0 | 3.5 | 0 | 3.5 | 3.5 | 0 | 0 | 0 |
| Goodwill | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 |
| Long Term Investments | 5.7 | 30.4 | 145.9 | 124.5 | 15.5 | 17.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Long Term Assets | 2.1 | 1.9 | 1.8 | 1.4 | 1.5 | 1.2 | 0.3 | 0.3 | 0.3 | 0.1 | 33 K | 31 K | 32 K |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 825.6 | 1 089.7 | 1 084.9 | 979.8 | 676.7 | 319.0 | 211.0 | 190.1 | 131.8 | 58.7 | 26.7 | 25.4 | 22.8 |
| LIABILITIES | |||||||||||||
| Accounts Payable | 94.6 | 101.0 | 59.4 | 21.9 | 27.8 | 19.7 | 17.4 | 13.1 | 8.4 | 5.0 | 2.5 | 2.5 | 2.5 |
| Short Term Debt | 25.4 | 25.4 | 14.0 | 6.9 | 5.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | 0.2 |
| Other Current Liabilities | 75.1 | 39.3 | 26.8 | 23.7 | 14.2 | 19.2 | 6.3 | 94 K | 0 | 0 | 17.5 | 0 | 0 |
| Total Current Liabilities | 197.3 | 171.3 | 100.4 | 52.8 | 48.0 | 38.9 | 23.8 | 13.5 | 11.4 | 12.9 | 20.4 | 23.8 | 22.4 |
| Long Term Debt | 618.9 | 483.0 | 98.0 | 85.1 | 30.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 |
| Deferred Tax Income | 0 | 0 | (3.0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 155.1 | 172.2 | 3.0 | 3.2 | 0.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 971.3 | 826.4 | 201.3 | 141.1 | 79.6 | 38.9 | 23.8 | 13.5 | 11.4 | 12.9 | 20.4 | 23.8 | 22.6 |
| EQUITY | |||||||||||||
| Common Stock | 7.7 | 7.7 | 7.6 | 7.2 | 6.4 | 5.7 | 5.0 | 4.4 | 3.4 | 2.3 | 1.4 | 1.4 | 1.4 |
| Retained Earnings | (2 279.0) | (1 855.3) | (1 414.6) | (1 030.3) | (611.3) | (393.3) | (263.2) | 159.3 | 111.3 | 39.6 | 2.1 | (1.9) | (3.2) |
| Other Accumulative Comprehensive Income/Loss | (153.4) | 255.7 | 876.0 | 831.5 | 590.7 | 274.4 | 182.2 | 13.0 | 5.7 | 4.0 | 2.7 | 2.1 | 2.0 |
| Total Equity | (145.7) | 263.3 | 883.6 | 838.7 | 597.1 | 280.1 | 187.2 | 176.6 | 120.3 | 45.8 | 6.3 | 1.6 | 0.2 |
| Total Liabilities and Equity | 825.6 | 1 089.7 | 1 084.9 | 979.8 | 676.7 | 319.0 | 211.0 | 190.1 | 131.8 | 58.7 | 26.7 | 25.4 | 22.8 |
| SHARES OUTSTANDING | |||||||||||||
| Common Shares Outstanding | 56.3 | 56.1 | 54.8 | 50.6 | 46.5 | 41.1 | 33.6 | 26.6 | 23.7 | 16.9 | 10.8 | 10.8 |